TP-472

• UNSPSC Description:

  TP-472 is a selective BRD9/7 inhibitor, with Kds of 33 nM and 340 nM for BRD9 and BRD7, respectively. TP-472 exhibits >30-fold selectivity for BRD9 over other bromodomain family members except BRD7[1][2]. TP-472 induces apoptosis of melanoma cells[3].

• Target Antigen:

  Apoptosis; Epigenetic Reader Domain

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Epigenetics

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/tp-472.html

• Purity:

  99.52

• Solubility:

  DMSO : 100 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  O=C(C)C1=CC(C2=C(C)C=CC(C(NC3CC3)=O)=C2)=C4N=CC=CN41

• Molecular Weight:

  333.38

• References & Citations:

  [1]Gatchalian J, et al. A non-canonical BRD9-containing BAF chromatin remodeling complex regulates naive pluripotency in mouse embryonic stem cells. Nat Commun. 2018 Dec 3;9(1):5139.|[2]Moustakim M, et al. Chemical probes and inhibitors of bromodomains outside the BET family. Medchemcomm. 2016 Dec 7;7(12):2246-2264.|[3]Lawrence David Mason, et al. The BRD9/7 Inhibitor TP-472 Blocks Melanoma Tumor Growth by Suppressing ECM-Mediated Oncogenic Signaling and Inducing Apoptosis. Cancers (Basel). 2021 Nov 3;13(21):5516.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  2079895-62-6